Segulah Advisor
VC Fund
Stockholm, Sweden
Segulah Advisor is a VC fund in Stockholm focused on Medical Device and Apps. Segulah is a Nordic private equity firm. We currently manage 8.5 billion Swedish kronor invested in three funds: Segulah II, L.P., Segulah III, L.P. and Segulah IV, L.P.International pension funds, endowments and insurance companies are our primary sources of capital commitments.In our role as owner we appoint boards of directors, which givetight support to management and foster continued development of the business.We recruit prospective board directors from our network of industrial advisors. More information can be found under Team
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $294M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Segulah Advisor invests in
Stages Segulah Advisor invests in
Countries Segulah Advisor invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Medical Device 2 (40%)
- Apps 1 (20%)
- Credit 1 (20%)
- Mobile 1 (20%)
- FinTech 1 (20%)
Stage
- Series A 1 (20%)
- Series D 1 (20%)
- Post-IPO Debt 1 (20%)
- Private Equity 1 (20%)
Country
- Sweden 3 (60%)
- United Kingdom 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cecilia Åfeldt
Investment Controller
|
Investment Controller | Total investments: 0 | Find email | |
Gabriel Urwitz
Founder
|
Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Senzime
|
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in bothblood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. | $5.6M / Post-IPO Debt / Feb 18, 2026 | |
Co-native
|
Co-native is establishing a family of cloud specialized enterprises in microsoft, AWS, and google cloud, providing the most appealing alternative for future growth. | Private Equity / Jun 17, 2022 | |
|
Co-native
|
Co-native is establishing a family of cloud specialized enterprises in microsoft, AWS, and google cloud, providing the most appealing alternative for future growth. | Private Equity / Jun 17, 2022 | |
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $245M / Series D / Jun 23, 2021 | |
Kreditz
|
Kreditz makes sense out of open banking/PSD2-data with their proprietary Analytics Categorization Engine (ACE). By using ACE, Kreditz is able to fine-tune the transaction data (from any AISP-data aggregator) to make it understandable and usable in valid functional products such as income verification, credit scoring, KYC and many more. Theproducts are available both by API or by an integration-free Web portal. Kreditz serves industries such as consumer- & SME-lending, money transfer, auditing, gambling/betting, insurance and more throughout the Nordic countries. | $1.9M / Series A / Apr 08, 2020 |
Co-Investors
Ancora
1 deal together
BlackRock
1 deal together
b2venture
1 deal together
DBT
1 deal together
Eldridge Industries
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Segulah Advisor invest in?
Segulah Advisor invests primarily in Medical Device, Apps and Credit startups, most often at Series A and Series D stage. Most of the 5 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Segulah Advisor?
Public channels for Segulah Advisor include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Segulah Advisor?
The team at Segulah Advisor includes Cecilia Åfeldt (Investment Controller) and Gabriel Urwitz (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
